BriaCell Therapeutics Corp. (BCTX)

$6.4

-0.13 (-1.99%)
Rating:
Recommendation:
-
Symbol BCTX
Price $6.4
Beta 1.376
Volume Avg. 0.36M
Market Cap 100.162M
Shares () -
52 Week Range 4.06-12.47
1y Target Est -
DCF Unlevered BCTX DCF ->
DCF Levered BCTX LDCF ->
ROE -26.80% Sell
ROA -29.73% Sell
Operating Margin -
Debt / Equity 1.41% Neutral
P/E -
P/B 2.15 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BCTX news


Healthcare
Biotechnology
NASDAQ Capital Market

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.